![](https://d3ilqtpdwi981i.cloudfront.net/zs4g9ylciVw6jyrmxTSkmNjNXsc=/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/44/f5/5c/44f55c20-e187-49d9-acd4-1efa37b056cd/file.jpg)
Article
The use of 3′-deoxy-3′-18F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy
Annals of Nuclear Medicine
(2019)
Disciplines
Publication Date
June 1, 2019
DOI
10.1007/s12149-019-01345-w
Citation Information
Benjamin E. Ueberroth, Jawana M. Lawhorn-Crews, Lance K. Heilbrun, Daryn W. Smith, et al.. "The use of 3′-deoxy-3′-18F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy" Annals of Nuclear Medicine Vol. 33 Iss. 6 (2019) p. 383 - 393 Available at: http://works.bepress.com/nicole-eiseler/1/